Laurus Labs invests ₹1,078 crore in Krka Pharma, retains 49% stake
- Invested ₹1,078 crore in Krka Pharma via rights issue
- Acquired 107.8 million shares at face value of ₹10 each
- Maintains 49% stake in the joint venture with KRKA d.d.
- Total holding rises to 262.15 million equity shares
*this image is generated using AI for illustrative purposes only.
Laurus Labs invested ₹1,078 crore in Krka Pharma Private Limited through a rights issue, acquiring 107.8 million shares to maintain its 49% equity stake in the joint venture.
Investment details
The transaction was executed by way of a rights issue where Laurus Labs acquired equity shares at a face value of ₹10 each. The investment reinforces the company's position in the joint venture with KRKA d.d., Novo mesto, Slovenia.
| Parameter | Details |
|---|---|
| Investment amount | ₹1,078 crore |
| Mode of investment | Rights issue |
| Shares acquired | 107.8 million |
| Face value per share | ₹10 |
| Investee company | Krka Pharma Private Limited |
| Post-investment stake | 49% |
| Total holding | 262.15 million shares |
Joint venture structure
Krka Pharma is a joint venture between Laurus Labs and KRKA d.d., Novo mesto, Slovenia. Following this capital infusion, the total holding of Laurus Labs in Krka Pharma stands at 262.15 million equity shares. Despite the additional investment, the percentage of shareholding held by Laurus Labs remains unchanged at 49%.
The company disclosed this update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, referencing an earlier intimation dated April 30, 2026. The filing confirms that the funds were deployed strictly for the acquisition of new equity shares issued during the rights issue period.
Historical Stock Returns for Laurus Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.09% | -0.64% | +3.45% | +87.25% | +132.97% | +221.08% |
How will the additional ₹1,078 crore capital infusion specifically accelerate Krka Pharma's expansion plans in the Indian generic drug market?
What are the projected revenue synergies expected from this strengthened Laurus Labs-KRKA partnership over the next three fiscal years?
Does the unchanged 49% stake indicate any potential future strategic shifts or full acquisition possibilities for either partner?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
